Skip to main content

Table 3 Baseline demographic and clinical variables and domain scores associated with treatment duration

From: Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment

Variables Univariatea Multivariatea
HR (95 % CI) P value HR (95 % CI) P value
Baseline characteristics
Age <70 y (vs. ≥70 y) 0.749 (0.343–1.429) 0.380   
Sex, male (vs. female) 0.634 (0.307–1.308) 0.217   
HCV infection (vs. other etiology) 1.796 (0.964–3.348) 0.065   
Child Pugh = 5 (vs. ≥6) 0.511 (0.271–0.962) 0.038   
TMN stage III (vs. IV) 0.672 (0.357–1.264) 0.218   
Vascular invasion – (vs. +) 0.355 (0.178–0.710) 0.003 0.382 (0.186–0.786) 0.009
Tumor size <50 mm (vs. ≥50 mm) 0.777 (0.412–1.466) 0.432   
Previous curative therapy: Yes (vs. No) 0.433 (0.226–0.829) 0.012   
AFP <100 (vs. ≥100) 1.048 (0.561–1.961) 0.954   
DCP <1000 (vs. ≥1000) 0.473 (0.509–0.912) 0.025 0.509 (0.261–0.993) 0.048
Initial dose of sorafenib 800 mg (vs. <800 mg) 0.744 (0.388–1.426) 0.373   
HRQOL domain scores ≥40:b
Physical functioning 0.956 (0.509–1.799) 0.889   
Role physical 0.771 (0.416–1.429) 0.408   
Bodily pain 1.582 (0.728–3.436) 0.247   
General health 1.034 (0.516–2.070) 0.926   
Vitality 1.534 (0.631–3.731) 0.346   
Social functioning 0.395 (0.185–0.840) 0.016 0.452 (0.206–0.995) 0.049
Role emotional 0.898 (0.455–1.770) 0.755   
Mental health 0.833 (0.379–1.828) 0.649   
  1. HR hazard ratio, CI confidence interval, HCV hepatitis C virus, TNM tumor-node-metastasis, AFP alpha fetoprotein, DCP des-gamma-carboxy prothrombin; HRQOL, health related quality of life
  2. aCox proportional hazards regression analysis
  3. bAll domain scores are relative to scores <40
  4. All variables with P values <0.05 in the univariate analysis were included in the multivariate analysis